Breast Cancer Research and Treatment

, Volume 120, Issue 3, pp 627–637

Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer

  • So-Youn Jung
  • Hyun Yul Kim
  • Byung-Ho Nam
  • Sun Young Min
  • Seung Ju Lee
  • Chansung Park
  • Youngmee Kwon
  • Eun-A Kim
  • Kyoung Lan Ko
  • Kyung Hwan Shin
  • Keun Seok Lee
  • In Hae Park
  • Seeyoun Lee
  • Seok Won Kim
  • Han-Sung Kang
  • Jungsil Ro
Clinical trial

Abstract

The present study was designed to assess the clinical characteristics and outcomes of metaplastic breast cancer (MBC) compared to general invasive ductal carcinoma (IDC) and the triple-negative subtype (TN-IDC). The study population included 35 MBC and 2,839 IDC patients, including 473 TN-IDC diagnoses, from the National Cancer Center, Korea between 2001 and 2008. The clinicopathological characteristics and clinical outcomes were retrospectively reviewed. Mean age of patients was 47.4 years for the MBC group and 48.3 years for the IDC group. The MBC patients presented with a larger tumor size (≥T2, 74.3% vs. 38.8%, P < 0.001), more distant metastasis at the first diagnosis (8.6% vs. 2.0%, P = 0.04), higher histologic grade (grade 3, 65.7% vs. 41.4%, P < 0.001), fewer estrogen receptor (ER), and progesterone receptor (PgR) positivity (ER+, 5.7% vs. 65.4%, P < 0.001; PgR+, 8.6% vs. 55.8%, P < 0.001), higher Ki-67 expression (35.5 ± 26.2% vs. 20.6 ± 19.8%, P = 0.024), and more TN subtypes (80.0% vs. 16.7%, P < 0.001) compared to the IDC group. Fifteen (46.8%) MBC patients and 260 (9.3%) IDC patients experienced disease recurrence with a median follow-up of 47.2 months (range 4.9–100.6 months). MBC was a poor prognostic factor for disease recurrence and overall survival in univariate and multivariate analysis (HR 3.89 in recurrence, 95% CI: 1.36–11.14, P = 0.01; HR 5.29 in death, 95% CI: 2.15–13.01, P < 0.001). MBC patients also experienced more disease recurrence (HR 3.99, 95% CI: 1.31–12.19, P = 0.01) and poorer overall survival (HR 3.14, 95% CI: 1.19–8.29, P = 0.02) compared to the 473 TN-IDC patients, as reflected by aggressive pathological features. Patients with MBC appeared to have inherently aggressive tumor biology with poorer clinical outcomes than those with general IDC or TN-IDC.

Keywords

Metaplastic breast cancer Triple-negative Invasive ductal carcinoma Prognosis 

Supplementary material

10549_2010_780_MOESM1_ESM.pdf (22 kb)
Supplementary material 1 (PDF 21 kb)

References

  1. 1.
    Schnitt SJ, Guidi AJ (2000) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 2nd edn. Lippincott, Williams and Wilkins, Philadelphia, pp 440–443Google Scholar
  2. 2.
    Oberman HA (1987) Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 11:918–929CrossRefPubMedGoogle Scholar
  3. 3.
    Gunhan-Bilgen I, Memis A, Ustun EE, Zekioglu O, Ozdemir N (2002) Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. Am J Roentgenol 178:1421–1425Google Scholar
  4. 4.
    Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 21:1142–1150CrossRefPubMedGoogle Scholar
  5. 5.
    Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 65:272–276CrossRefPubMedGoogle Scholar
  6. 6.
    Wargotz ES, Deos PH, Norris HJ (1989) Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 20:732–740CrossRefPubMedGoogle Scholar
  7. 7.
    Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 20:628–635CrossRefPubMedGoogle Scholar
  8. 8.
    Carter MR, Hornick JL, Lester S, Fletcher CD (2006) Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol 30:300–309PubMedGoogle Scholar
  9. 9.
    Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN (1999) Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 10:413–419CrossRefPubMedGoogle Scholar
  10. 10.
    Brenner RJ, Turner RR, Schiller V, Arndt RD, Giuliano A (1998) Metaplastic carcinoma of the breast: report of three cases. Cancer 82:1082–1087CrossRefPubMedGoogle Scholar
  11. 11.
    Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173CrossRefPubMedGoogle Scholar
  12. 12.
    Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMedGoogle Scholar
  13. 13.
    Sorlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40:2667–2675CrossRefPubMedGoogle Scholar
  14. 14.
    Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMedGoogle Scholar
  15. 15.
    Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334CrossRefPubMedGoogle Scholar
  16. 16.
    Nam BH, Kim SY, Han HS et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10:R20CrossRefPubMedGoogle Scholar
  17. 17.
    McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184PubMedCrossRefGoogle Scholar
  18. 18.
    Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar
  19. 19.
    Henson DE, Ries L, Freedman LS, Carriaga M (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68:2142–2149CrossRefPubMedGoogle Scholar
  20. 20.
    Tomasello G, de Azambuja E, Dinh P et al (2008) Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 8:1883–1890CrossRefPubMedGoogle Scholar
  21. 21.
    Moy B, Goss PE (2007) TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 7:489–492CrossRefPubMedGoogle Scholar
  22. 22.
    Chao TC, Wang CS, Chen SC, Chen MF (1999) Metaplastic carcinomas of the breast. J Surg Oncol 71:220–225CrossRefPubMedGoogle Scholar
  23. 23.
    Dave G, Cosmatos H, Do T, Lodin K, Varshney D (2006) Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys 64:771–775PubMedGoogle Scholar
  24. 24.
    Chhieng C, Cranor M, Lesser ME, Rosen PP (1998) Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am J Surg Pathol 22:188–194CrossRefPubMedGoogle Scholar
  25. 25.
    Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 64:1490–1499CrossRefPubMedGoogle Scholar
  26. 26.
    Luini A, Aguilar M, Gatti G et al (2007) Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 101:349–353CrossRefPubMedGoogle Scholar
  27. 27.
    Lien HC, Hsiao YH, Lin YS et al (2007) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26:7859–7871CrossRefPubMedGoogle Scholar
  28. 28.
    Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • So-Youn Jung
    • 1
  • Hyun Yul Kim
    • 1
  • Byung-Ho Nam
    • 2
  • Sun Young Min
    • 1
  • Seung Ju Lee
    • 1
  • Chansung Park
    • 1
  • Youngmee Kwon
    • 1
  • Eun-A Kim
    • 1
  • Kyoung Lan Ko
    • 1
  • Kyung Hwan Shin
    • 1
  • Keun Seok Lee
    • 1
  • In Hae Park
    • 1
  • Seeyoun Lee
    • 1
  • Seok Won Kim
    • 1
  • Han-Sung Kang
    • 1
  • Jungsil Ro
    • 1
  1. 1.Center for Breast Cancer, National Cancer CenterIlsandong-gu, Goyang-si, Gyeonggi-doRepublic of Korea
  2. 2.Cancer Biostatistics Branch, Research Institute for National Cancer Control and EvaluationGoyangKorea

Personalised recommendations